Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.2.407

Predictive Role of Neutrophil Gelatinase-Associated Lipocalin in Early Diagnosis of Platin-Induced Renal Injury  

Seker, Mehmet Metin (Medical Oncology Department, Faculty of Medicine, Cumhuriyet University)
Deveci, Koksal (Biochemistry Department, Faculty of Medicine, Cumhuriyet University)
Seker, Ayse (Public Health Directorate)
Sancakdar, Enver (Biochemistry Department, Faculty of Medicine, Cumhuriyet University)
Yilmaz, Ali (Internal Medicine Department, Faculty of Medicine, Cumhuriyet University)
Turesin, A. Kerim (Internal Medicine Department, Faculty of Medicine, Cumhuriyet University)
Kacan, Turgut (Medical Oncology Department, Faculty of Medicine, Cumhuriyet University)
Babacan, Nalan A. (Medical Oncology Department, Faculty of Medicine, Cumhuriyet University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.2, 2015 , pp. 407-410 More about this Journal
Abstract
Background: Acute kidney injury is an important issue in chemotherapy receiving patients an neutrophil gelatinase-associated lipocalin has been proposed as a novel marker. We here aimed to assess the role of urinary levels for assessment after platin exposure. Materials and Methods: Patients who had treated with cisplatin or carboplatin or oxaliplatin containg regimens were included in this study. Baseline and postchemotherapy serum urea, creatinine, urine neutrophil gelatinase-associated lipocalin and urine creatinine levels were determined. To avoid the effects of hydration during chemotherapy infusion the urinary neutrophil gelatinase-associated lipocalin/urine creatinine ratio was used to determine acute kidney injury. Results: Of a total of 42 patients receiving platin compounds,14 (33.3%) received cisplatin containing regimens, 14 (33.3%) received carboplatin and 14 (33.3%) oxaliplatin. The median age was 60 (37-76) years. Nineteen of the patients (45.2%) had lung cancer, 12 (28.6%) colorectal cancer and 11 (26.2%) others. The median pre and post chemotherapy urine neutrophil gelatinase-associated lipocalin/urine creatinin ratio was 15.6 ng/mg and 35.8 ng/mg (p=0.041) in the cisplatin group, 32.5 ng/mg and 86.3 ng/mg (p=0.004) in the carboplatin group and 40.9 ng/mg and 62.3 ng/mg (p=0.243) in the oxaliplatin group. Conclusions: Nephrotoxicity is a serious side effect of chemotherapeutic agentslike cisplatin and carbopaltin, but only to a lower extent oxaliplatin. All platin compounds must be used carefully and urine neutrophil gelatinase-associated lipocalin measurement seems to be promising in detecting acute kidney injury earlier than with creatinine.
Keywords
Neutrophil gelatinase-associated lipocalin; cancer; platin chemotherapy; nephrotoxicity;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S (2006). Neutrophil-gelatinaseassociated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol, 26, 287-92.   DOI
2 Bennett M, Dent CL, Ma Q, et al (2008). Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol, 3, 665-73.   DOI
3 Berry DA, Cronin KA, Plevritis SK, et al (2005). Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med, 353, 1784-92.   DOI
4 Brawley OW (2011). Avoidable cancer deaths globally. CA Cancer J Clin, 61, 67-8.   DOI
5 Devarajan P (2008). Neutrophil gelatinase-associated lipocalin--an emerging troponin for kidney injury. Nephrol Dial Transplant, 23, 3737-43.   DOI
6 Gaspari F, Cravedi P, Mandala M, et al (2010). Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. Nephron Clin Pract, 115, 154-60.   DOI
7 Haase M, Bellomo R, Devarajan P, et al (2009). Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis, 54, 1012-24.   DOI
8 Haase M, Haase-Fielitz A, Bellomo R, et al (2009). Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial. Crit Care Med, 37, 39-47.   DOI
9 Haase M, Haase-Fielitz A, Bellomo R, Mertens PR (2011). Neutrophil gelatinase-associated lipocalin as a marker of acute renal disease. Curr Opin Hematol, 18, 11-8.   DOI
10 Haase M, Mertens PR (2010). Urinary biomarkers--silver bullets to faster drug development and nephron protection. Nephrol Dial Transplant, 25, 3167-9.   DOI
11 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
12 Kos FT, Sendur MA, Aksoy S, et al (2013). Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy. Asian Pac J Cancer Prev, 14, 1111-4.   DOI
13 Launay-Vacher V, Oudard S, Janus N, et al (2007). Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer, 110, 1376-84.   DOI
14 Lichtman SM, Wildiers H, Launay-Vacher V, et al (2007). International society of geriatric oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer, 43, 14-34.   DOI
15 Lin HY, Lee SC, Lin SF, et al (2013). Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatininduced acute kidney injury better than albuminuria or urinary cystatin C levels. Kaohsiung J Med Sci, 29, 304-11.   DOI
16 Ling W, Zhaohui N, Ben H, et al (2008). Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract, 108, 176-81.   DOI
17 Mishra J, Mori K, Ma Q, et al (2004). Neutrophil gelatinaseassociated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol, 24, 307-15.   DOI
18 Malyszko J, Bachorzewska-Gajewska H, Poniatowski B, Malyszko JS, Dobrzycki S (2009). Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Ren Fail, 31, 910-9.   DOI
19 Mishra J, Dent C, Tarabishi R, et al (2005). Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet, 365, 1231-8.   DOI
20 Mishra J, Ma Q, Prada A, et al (2003). Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol, 14, 2534-43.   DOI
21 Nickolas TL, Barasch J, Devarajan P (2008). Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens, 17, 127-32.   DOI
22 Parikh CR, Devarajan P (2008). New biomarkers of acute kidney injury. Crit Care Med, 36, 159-65.   DOI
23 Siegel R, Ward E, Brawley O, Jemal A (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 61, 212-36.   DOI
24 Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA (2009). Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol, 27, 2758-65.   DOI
25 Wagener G, Jan M, Kim M, et al (2006). Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology, 105, 485-91.   DOI